Rhythm Pharmaceuticals Inc.
NASDAQ:RYTM
| Market Cap (Intraday) | 3.10B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $50.74 |
| 50-Day MA | $48.29 |
| 200-Day MA | $44.13 |
Rhythm Pharmaceuticals Inc. Stock, NASDAQ:RYTM
222 Berkeley Street, 12th floor, Boston, Massachusetts 02116-3748
United States of America
Phone: +1.857.264.4280
Number of Employees: 226
Description
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.